Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

Exclusion Criteria

• •Treatment with an investigational or non-approved drug within one month
• •An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures
• •A history of allergies to any active or inactive ingredients of Faslodex (i.e. castor oil)
• •Treatment with more than one regimen of chemotherapy for advanced breast cancer
• •Treatment with more than one regimen of hormonal treatment for advanced breast cancer